Drugs / MIGOPROTAFIB
MIGOPROTAFIB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05954871 | Jan 2024 → Sep 2025 | colorectal cancer, non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05487235 | Aug 2022 → Jun 2025 | cancer, metastatic neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04449874 | Jul 2020 → Dec 2027 expected | colorectal cancer, non-small cell lung carcinoma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04252339 | Feb 2020 → Nov 2022 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-14 | Relay Therapeutics, Inc. | Relay Therapeutics® Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971 relaytx.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIGOPROTAFIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314471 ↗ |
| Known as | GDC-1971 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04449874 ↗ |
| Known as | RG-6433 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314471 ↗ |
| Known as | RLY-1971 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04252339 ↗ |
| Known as | RO-7517834 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314471 ↗ |
| Known as | RTX-1084260 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314471 ↗ |
| Action | Inhibit | “RLY-1971 is an oral inhibitor of SHP2.” NCT04252339 ↗ |
| Modality | Small molecule | — CHEMBL5314471 ↗ |
| Route | Oral | “RLY-1971 is an oral inhibitor of SHP2.” NCT04252339 ↗ |